General Hospital Venizeleio-Pananeio

The Cardiology department at General Hospital Venizeleio-Pananeio focuses on advancing care for patients with heart failure, atrial fibrillation, hypertension and high cardiovascular risk. Trials aim to test new therapeutic combinations and anti‑inflammatory strategies to improve survival and reduce hospitalizations.

• Restoration of sinus rhythm in recent onset atrial fibrillation
• Anti‑inflammatory agents for heart failure with preserved ejection fraction
• Combination therapies to lower cardiovascular death and heart‑failure admissions
• Renal‑protective approaches in patients with established cardiovascular disease

The site leverages its cardiac unit to enroll local patients and contribute to international cardiovascular research.

Research in the digestive tract concentrates on ulcerative colitis, targeting both induction of remission and long‑term safety of novel biologic agents. The studies seek to enhance treatment durability and quality of life for patients with moderate to severe disease.

• Induction of clinical remission in moderate to severe ulcerative colitis
• Long‑term safety monitoring of biologic therapy for ulcerative colitis
• Biomarker‑guided treatment strategies in inflammatory bowel disease

The hospital’s gastroenterology team collaborates closely with cardiology to manage patients with overlapping comorbidities.

The immune‑mediated kidney program investigates therapies for IgA nephropathy, aiming to reduce proteinuria and preserve renal function. Trials evaluate monoclonal antibodies that modulate immune pathways implicated in renal injury.

• Proteinuria reduction in IgA nephropathy
• Targeting immune mechanisms in renal disease
• Safety and efficacy of novel monoclonal antibodies for immune‑mediated kidney disorders

This work positions the site as a hub for kidney‑focused immune research within the region.

Studies address type 2 diabetes, obesity and related metabolic disorders. The goal is to assess combination regimens that improve glycaemic control, promote weight loss, and lower cardiovascular events in high‑risk populations.

• Combining metabolic modulators with SGLT2 inhibitors
• Weight‑management strategies for diabetic patients with heart failure
• Impact of novel agents on blood glucose and body weight

The multidisciplinary approach integrates endocrinology, cardiology and nutrition services at the hospital.

The respiratory research portfolio includes trials for chronic obstructive pulmonary disease (COPD), focusing on reducing exacerbations, especially in former smokers. Anti‑inflammatory compounds are evaluated for their ability to improve lung outcomes while monitoring cardiovascular safety.

• Reducing moderate to severe exacerbations in COPD
• Evaluating anti‑inflammatory therapy in former smokers
• Safety of respiratory drugs in patients with cardiovascular comorbidities

Collaboration with pulmonary specialists ensures comprehensive care for participants.

Beyond the core therapeutic areas, the site conducts studies on rare and oncologic conditions such as transthyretin amyloidosis with cardiomyopathy and metastatic castration‑sensitive prostate cancer. Objectives include disease‑modifying treatment evaluation and integration of cardiac and metabolic care.

• Disease‑modifying therapy for transthyretin amyloidosis with cardiomyopathy
• Targeted treatment strategies in metastatic castration‑sensitive prostate cancer
• Integrated care approaches for patients with overlapping cardiac and metabolic conditions

These programs broaden the research scope of General Hospital Venizeleio-Pananeio, attracting diverse patient populations.